Citigroup Inc Neurocrine Biosciences Inc Call Options Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 12, 2024	BUY	$114.58 - $153.15 $5.25 Million - $7.01 Million	45,800 New	45,800 $5.27 Million
Q4 2023 Feb 09, 2024	BUY	$106.07 - $132.76 $3.18 Million - $3.98 Million	30,000 New	30,000 $3.95 Million
Q2 2023 Aug 10, 2023	BUY	$89.53 - $104.87 $2.69 Million - $3.15 Million	30,000 Added 100.0%	60,000 $5.66 Million
Q1 2023 May 11, 2023	BUY	$94.11 - $123.02 $2.82 Million - $3.69 Million	30,000 New	30,000 $3.04 Million
Q3 2022 Nov 10, 2022	BUY	$92.03 - $107.81 $1.63 Million - $1.91 Million	17,700 Added 1361.54%	19,000 $2.02 Million
Q2 2022 Aug 10, 2022	BUY	$75.79 - $100.07 $98,527 - $130,090	1,300 New	1,300 $127,000

626

94M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.